Australia's Immutep soars on partnering with India's Dr. Reddy’s

Immutep

09/12/2025 02:39

** Shares of Immutep IMM.AX rise as much as 31.4% to A$0.335, their biggest intraday pct gain since May 18, 2023
** Biotech co partners with India's Dr. Reddy’s Laboratories REDY.NS for commercialization of Eftilagimod Alfa, an Oncology drug
** Dr. Reddy’s receives exclusive rights to develop and commercialize the drug in all countries outside North America, Europe, Japan, and Greater China
** Immutep will receive $20 million upfront, eligible for milestone payments of up to $349.5 million plus royalties on commercial sales
** Shares hit highest level since May 6
** YTD, IMM shares down 12.3%

 (Reporting by Nichiket Sunil in Bengaluru)

 ((Nichiket.Sunil@thomsonreuters.com))